Treatments

The mRNA vaccines made by Moderna as well as the partnership between Pfizer-BioNTech are also cleared for use by this age group, the Medicines and Healthcare products Regulatory Agency (MHRA) said. ...

Country / Region Tags:

Global

UK - London

General Topic Tags:

Problem, Solution, SitRep, or ?:

Situation Report

Read more about UK approves Novavax COVID shot for 12-17 year-olds
Log in or register to post comments

US: COVID vaccination in kids under 5 remain low as US hospital admissions steadily rise

Fri, 2022-08-26 10:07 — mike kraft

COVID vaccination in kids under 5 remain low as US hospital admissions steadily rise Summer hospitalizations saw an increase in younger kids, and experts worry the trend will continue as children return to school and day care. YahooNews

...

Country / Region Tags:

General Topic Tags:

Problem, Solution, SitRep, or ?:

Situation Report

Read more about US: COVID vaccination in kids under 5 remain low as US hospital admissions steadily rise
Log in or register to post comments

Country- by- country report on vaccines delivered to poorer nations by international agency

Fri, 2022-08-26 09:59 — mike kraft

Factbox: Vaccines delivered under COVAX sharing scheme for poorer countries The COVAX facility, backed by the World Health Organization (WHO) and the Global Alliance for Vaccines and Immunization (GAVI), has delivered 1.63 billion COVID-19 vaccine doses to 146 countries, GAVI data shows. Reuters Reuters

Country / Region Tags:

General Topic Tags:

Problem, Solution, SitRep, or ?:

Situation Report

Read more about Country- by- country report on vaccines delivered to poorer nations by international agency
Log in or register to post comments

Moderna sued Pfizer and BioNTech, accusing them of copying the central technology behind its coronavirus vaccine.

Fri, 2022-08-26 09:36 — mike kraft

Moderna files patent infringement lawsuits against Pfizer and BioNTech over mRNA Covid-19 vaccines | CNN Moderna on Friday filed patent infringement lawsuits against Pfizer and BioNTech "for infringing patents central to (its) mRNA technology platform," the company said in a news release Friday. Ben Tinker,Amanda Sealy CNN

...

Country / Region Tags:

General Topic Tags:

Problem, Solution, SitRep, or ?:

Situation Report

Explainer: Updated COVID-19 vaccines are expected in the U.S. next month, considerations in getting one

Thu, 2022-08-25 09:18 — mike kraft

Explainer: Updated COVID-19 vaccines are coming in the U.S., should you get one? The United States plans to roll out an updated COVID-19 booster vaccine to include Omicron subvariants of the coronavirus. Regulators are reviewing the shots and could give the go-ahead as soon as next week. Ahmed Aboulenein,Julie Steenhuysen Reuters

Country / Region Tags:

General Topic Tags:

Problem, Solution, SitRep, or ?:

Analysis

Congressional panel releases details of Trump pressure on FDA for discredited hydroxychloroquine COVID treatment

Wed, 2022-08-24 17:51 — mike kraft

House panel details Trump pressure on FDA for discredited COVID treatment, vaccines Top Trump administration officials pressured the Food and Drug Administration (FDA) to reauthorize the discredited COVID-19 treatment hydroxychloroquine, and to speed up the release of the first CO… nweixel The Hill

Country / Region Tags:

General Topic Tags:

Problem, Solution, SitRep, or ?:

Analysis

Pfizer COVID pill showed no benefit in younger adults but helped older persons-study

Wed, 2022-08-24 17:17 — mike kraft

Study: Pfizer COVID pill showed no benefit in younger adults WASHINGTON (AP) — Pfizer's COVID-19 pill appears to provide little or no benefit for younger adults, while still reducing the risk of hospitalization and death for high-risk seniors, according to a large study published Wednesday. AP NEWS

...

The researchers found that Paxlovid reduced hospitalizations among people 65 and older by roughly 75% when given shortly after infection. That’s consistent with earlier results used to authorize the drug in the U.S. and other nations.

Country / Region Tags:

General Topic Tags: